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Abstract
Objective To compare characteristics and incidence of dis-
continuation of Parkinson’s disease (PD) patients starting
ropinirole or pramipexole in clinical practice with data from
randomised controlled clinical trials (RCTs).
Methods Included in the retrospective clinical-practice cohort
were first-time users of ropinirole or pramipexole diagnosed
with PD before 2005. Baseline characteristics and incidence
of discontinuation were compared between the clinical-
practice cohort and RCTs. Treatment discontinuation was
defined as more than 180 days between two refills of
ropinirole or pramipexole. The incidence of discontinuation
in RCTs was based on the reported rate of discontinuation for
any cause.
Results Included were 45 patients who started with ropinirole
and 59 patients who started with pramipexole. Treatment was
discontinued within 3 years in 51% (ropinirole) and 60%
(pramipexole) of the patients. Ten RCTs with ropinirole and
12 with pramipexole were identified. Baseline characteristics
did not differ between the clinical-practice cohort and RCTs.
RCTs reported discontinuation rates comparable with those at
the same timepoint in the clinical practice until 1 year of
follow-up.
Conclusion This study shows that the overall incidence of
discontinuation of ropinirole and pramipexole between the
patients in our clinical-practice cohort and patients in the
RCTs was comparable for the short term. However for
the long term, discontinuation in practice is possibly higher.
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RCTs Randomised controlled clinical trials
Introduction
Ropinirole and pramipexole, two non-ergoline dopamine
agonists with high binding characteristics for the dopamine
D2 receptor andwith a preferential affinity to the dopamine D3
receptor subgroup, were introduced during the past 10 years
for the treatment of Parkinson’s disease (PD). Compared
with levodopa, dopamine agonists have been associated with
a reduced risk of developing dyskinesias [1, 2]. There are
also indications—although arguable—that ropinirole and
pramipexole might slow disease progression [3–5]. There-
fore, it could be beneficial to continue (initial) non-ergoline
dopamine agonist therapy as long as possible.
Clinical trials frequently do not mirror daily practice [6].
In trials, the effects of drugs are examined for a limited
period of time, under well-controlled conditions and in a
homogeneous and highly selected group of patients. This
hampers generalisation of clinical trial data with regard to
efficacy, tolerability and safety to daily clinical practice.
Observational research within the setting of daily clinical
practice can complement the results of randomised controlled
clinical trials (RCTs). A useful measure of effectiveness in
observational studies, which encompasses both efficacy and
tolerability, is the incidence of drug discontinuation.
The objective of this study was to compare patient
characteristics and the incidence of discontinuation of
ropinirole or pramipexole between a clinical-practice cohort
with PD and data from RCTs.
Methods
Setting and study population
Clinical-practice cohort
The setting of this retrospective cohort study was the
neurology department of a large teaching hospital in
Enschede, The Netherlands. Included were outpatients
diagnosed with PD before 2005 who received ropinirole
or pramipexole for the first time. Prescription data were
retrieved from community pharmacies after obtaining the
patients’ informed consent. The date of first prescription of
ropinirole and pramipexole was defined as the index date.
To ascertain first-time use, patients were required to have at
least 180 days of prescription history for any medicine
before the index date. Patients were excluded if there were
prescription data for fewer than 180 days for any medicine
after the index date. The same patient could be included
two times: one time for ropinirole and one time for
pramipexole treatment.
RCTs
In order to identify published RCTs with ropinirole or
pramipexole treatment in PD patients, we performed a
Pubmed search with the keywords ‘ropinirole’ or ‘prami-
pexole’ and ‘Parkinson’s disease’ and the limits ‘random-
ized controlled trial’, ‘English language’ and ‘humans’.
Articles published until March 2007 that matched all
criteria were included. All references in selected articles
were screened and included when of interest. A cited
reference search in Web of Science was done in order to
identify missing articles. Finally, we performed a search in
the Cochrane central register of controlled trials.
Data analysis
Baseline characteristics
Baseline characteristics of the clinical-practice cohort were
recorded from the medical chart.
For each dopamine agonist, we pooled all RCTs that
included patients with early PD as well as patients already
using levodopa. The baseline characteristics of those
patients were weighted for the number of patients.
Incidence of discontinuation
The patients in the clinical-practice cohort were considered
to have discontinued treatment when more than 180 days
elapsed between two consecutive pharmacy refills of
ropinirole or pramipexole. Patients who persisted with
therapy to the end of their observation time were censored
on the last day of their follow-up. Consequently, patients
who may have moved to another place or died during
follow-up were censored on the last day of their follow-up.
Cumulative hazards of discontinuation were plotted against
the time of follow-up.
The incidence of discontinuation in the RCTs was based
on the reported rate of discontinuation for any cause and
was plotted per trial against the time of follow-up. A
Fisher’s exact test was used to compare the incidence of
discontinuation between the clinical-practice and RCT
cohorts at the timepoints 1, 2, 3 and 5 years of follow-up
for ropinirole or 1, 2 and 4 years of follow-up for
pramipexole.
In the clinical-practice cohort, a stratified Cox regression
analysis was performed to investigate whether there was a
difference in discontinuation between patients who used
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levodopa at baseline and those not using levodopa at
baseline.
Furthermore, an analysis was conducted to determine
whether other anti-parkinsonian treatment was started after
discontinuation of ropinirole or pramipexole (within an
interval of ± 90 days).
Results
Characteristics
From the clinical-practice cohort of 236 patients with PD,
we identified 45 patients who started with ropinirole and 59
patients who started with pramipexole between 1998 and
2005 and who met the inclusion criteria (Fig. 1). Fourteen
patients were included twice: once for ropinirole and once
for pramipexole treatment. From the literature, ten RCTs
with ropinirole met the criteria, of which one was a
6-month extension trial. Twelve RCTs with pramipexole
were identified, of which one was an extension trial.
The baseline characteristics in the clinical-practice
cohort and the RCTs are summarised in Table 1. The
median follow-up in the clinical-practice cohort was
2.0 years for the ropinirole users and 1.6 years for
pramipexole users. The follow-up time in the RCTs ranged
from 12 weeks to 5 years for ropinirole, and from 9 weeks
to 4 years for pramipexole. Three RCTs with ropinirole and
two trials with pramipexole had a follow-up period that was
longer than 1 year.
Incidence of discontinuation
In the clinical-practice cohort, 3 years after the initiation of
dopamine agonist therapy, 51% had discontinued ropinirole
and 60% had discontinued pramipexole (Fig. 2). There was
no statistically significant difference in discontinuation of
ropinirole or pramipexole treatment between patients who
used levodopa at baseline and those not using levodopa at
baseline. In the RCTs, the incidence of discontinuation ranged
from 7–53% for ropinirole and from 0–45% for pramipexole,
depending on the duration of follow-up in the RCT (Fig. 2).
As seen in Fig. 2, all five studies lasting more than 1 year
were below the discontinuation curve from the clinical-
practice cohort. Indeed, the discontinuation rates in the RCTs
were not significantly different from those at the same time-
point in the clinical practice cohort until 1 year of follow-up
for pramipexole. However, there was no statistically signifi-
cant difference until 5 years of follow-up for ropinirole.
In the clinical-practice cohort, two patients (8%) who
discontinued ropinirole treatment started with amantadine
and four patients (16%) started with an ergoline dopamine
agonist. One of the patients (3%) who discontinued
pramipexole treatment started with amantadine and one
patient (3%) with an ergoline dopamine agonist.
Discussion
The main observation from this retrospective clinical-
practice cohort study is that the incidence of discontinuation
236 outpatients diagnosed with PD
Excluded:
- No informed consent: 51
- No drug prescription data retrieved: 29
156 patients with drug prescription data
52 ropinirole users 64 pramipexole users
3 Excluded:
- less then 180 days drug history before index date 1
4 - less then 180 days of drug history after index date 4
45 initial 
ropinirole users Final study population
59 initial
pramipexole users
Fig. 1 Flow chart of inclusion
in clinical-practice cohort
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of ropinirole and pramipexole in our cohort was comparable
to that reported in RCTs for the short term. However, for the
long term, discontinuation in daily clinical practice is
possibly higher. This suggests that for these dopamine
agonists, only short-term discontinuation rates reported in
RCTs can be extrapolated to daily clinical practice.
All five long-term trials with a follow-up time extending
over 1 year differed from the short-term trials in several
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Fig. 2 Cumulative hazard of
discontinuation in the clinical-
practice cohort (solid lines, with
numbers of patients at risk be-
low) and the proportion of dis-
continuation in RCTs in patients
with Parkinson’s disease.
a Ropinirole: ♦ [17], ▪ [18], ▴
[19], x [20], Δ [21], ● [22], +
[1], ○ [23], - [24], ◊ [3].
b Pramipexole: — [25], - [26], ◊
[27], x [28], Δ [29], ● [30], ○
[31], ♦ [32], □ [33], + [34], ▴
[2], ▪ [35]










Male gender (%) 22 (48.9) 27 (45.8) 653 (60.0)a 750 (63.0)
Mean age (SD); range 66 (9.7); 48–91 68 (7.1); 48–80 63 (NA); NAa 63 (NA); NA
Mean duration of PD in months, (range) 68 (0–220) 81 (0–473) 55.7 (NA) 57.7 (NA)
Concomitant use of other anti-parkinsonian
drugs at index date (%)
Amantadine 10 (22.2) 8 (13.6) NA NA
Selegeline 6 (13.3) 1 (1.7) NA NA
Levodopa 34 (75.6) 34 (57.6) 522 (55.2)b 665 (55.8)
Apomorphine 2 (4.4) 2 (3.4) NA NA
Other dopamine agonist 1 (2.2) 6 (10.2) NA NA
Mean daily levodopa dosage at index date
in mg (SD); range
406 (290); 100–1369 595 (407); 100–1804 NA NA
Concomitant use of other medication at index date (%)
Antipsychotics 4 (8.9) 11 (18.6) NA NA
Antidepressants 6 (13.3) 0 (0) NA NA
Mean daily ropinirole or pramipexoleg dosage
in mg (SD); range
9.8 (8.5); 1.0–39.8c 2.0 (0.9); 0.5–4.8c 13.0 (NA); 3.3–17.9d,e,f 3.3 (NA); 2.8–4.1d,e,f
NA Not available
a One trial had no data
b Two trials had no data
c During follow-up
d At the end of follow-up
e Four trials had no data
f Range from means in trials
g As dihydrochloride monohydrate salt
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ways. Firstly, only patients with early PD not using
levodopa were included at baseline. Secondly, in contrast
with most of the short-term trials, levodopa rescue therapy
was allowed in the long-term trials. These facts may have
reduced the incidence of discontinuation of ropinirole and
pramipexole in the long-term trials. In daily clinical
practice, levodopa co-medication is also commonly used.
However, we hypothesize that in situations where rescue
medication is needed, clinicians tend more towards discon-
tinuation of dopamine agonist treatment in daily clinical
practice than in RCTs.
In addition to similar short-term discontinuation rates,
our patients also had similar baseline characteristics as
those reported in the RCTs. Our patients did differ from
those included in the RCTs in two ways. Firstly, some of
our patients used antipsychotics while starting with ropinir-
ole (9%) or pramipexole (19%), while antipsychotics users
were excluded in most of the RCTs. In daily clinical
practice, antipsychotic use in patients with PD is common
[7, 8]. Secondly, the mean dose of ropinirole or pramipexole
used was lower in our cohort than the maximum dose in the
RCTs. This is explained by the fact that we calculated the
mean dose over the entire follow-up, including the titration
phase. The dose reported in the RCTs is the maximum dose
at the end of follow-up, which is likely higher than the mean
dose. We have no indication that a larger number of patients
in the clinical-practice cohort would have led to other
estimates of baseline demographic items.
In another retrospective cohort study with PD patients of
80 years or older, 69% discontinued treatment with
ropinirole and 60% with pramipexole within the first
6 months [9]. In several other therapeutic areas, there have
been repeated examples of clear differences in patient
characteristics between RCTs and daily clinical practice
[10, 11]. Selective prescribing frequently occurs in daily
clinical practice [12, 13]. Differences in patient characteris-
tics may influence the frequency of benefit and harm of
therapy and thereby have important consequences for
assessing the therapeutic effects of a (relatively) new drug
in daily clinical practice. In this light, the similarity of
patient characteristics between RCTs and our clinical-
practice cohort is rather surprising but comforting, suggest-
ing that RCT data with pramipexole and ropinirole may be
generalised to daily clinical practice.
It would be clinically interesting to have knowledge
about which patients benefit from pharmacotherapy in daily
practice. In this study, we performed an additional analysis
to determine whether patient characteristics, including
antipsychotic or antidepressant use, were associated with
discontinuation of ropinirole or pramipexole using Cox
regression analysis. No statistical determinants for discon-
tinuation were detected. However, genetic determinants for
discontinuation should be investigated in the future [14].
The strength of the present study is the relatively long
follow-up of patients in the clinical-practice cohort and the
comparison with data from RCTs. However, there are
several possible limitations to our study. Firstly, we were
not able to retrieve the precise reasons for discontinuation
of ropinirole or pramipexole in our study. A major reason
for early discontinuation could be adverse effects [15].
Lack of efficacy also leads to early discontinuation. PD
patients often report a poor therapy response because they
expect an improvement in tremor, which occurs in only
about half of the cases [15]. Secondly, our definition of
discontinuation could be discussed. It is known that the
refill persistence is influenced by the maximum allowed
treatment gap [16], resulting in under- or overestimation of
the incidence of discontinuation. Discontinuation was
defined as patients for whom more than 180 days elapsed
between two consecutive pharmacy refills of ropinirole or
pramipexole, while the maximum length of prescription in
the Netherlands is 90 days. In our clinical-practice cohort,
the mean refill length of a prescription was 50 days for
ropinirole and 47 days for pramipexole. Therefore, we feel
that our results do not represent an overestimation of the
true incidence of discontinuation. Finally, we included
outpatients from only one hospital. Therefore, the results
could have been biased by the prescribing patterns of a few
clinicians.
In conclusion, this study shows that the overall charac-
teristics and incidence of discontinuation of ropinirole and
pramipexole between the patients in our clinical-practice
cohort and patients in the RCTs were comparable for the
short term. For the long term, discontinuation in practice is
possibly higher. More research is needed to investigate the
reasons and determinants of discontinuation in daily clinical
practice.
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